Molecular Cancer Therapeutics Strategies For Drug Discovery And Development George C Prendergast by George C. Prendergast 9780471432029, 9780471656166, 0471432024, 047165616X instant download after payment.

Molecular Cancer Therapeutics covers state-of-the-art strategies to identify and develop cancer drug target molecules and lead inhibitors for clinical testing. It provides a thorough treatment of drug target discovery, validation, and development. The introductory chapters provide an overview of pathways to discovery and development of molecular cancer therapeutics. Subsequent chapters progress from initial stages of drug target discovery to drug discovery, development, and testing in preclinical and clinical models. Topics include drug lead screening, drug-to-lead development, proof-of-concept studies, medicinal chemistry issues, intellectual property concerns, and clinical development.
This invaluable reference promotes understanding of steps involved in developing drug leads for industrial partnering and development. It provides an overview of the strategies for discovery and validation of drug target molecules, and discusses cell- and molecule-based drug screening strategies, as well as mouse models for cancer. Coverage also includes how to refine drug leads for suitability in clinical testing, the special issues of clinical testing of molecular-targeted drugs, and intellectual property concerns.Content:
Chapter 1 Introduction (pages 1–5): George C. Prendergast
Chapter 2 Molecular Cancer Therapeutics: Will the Promise be Fulfilled? (pages 7–40): Beverly A. Teicher
Chapter 3 Cancer Genetics and Drug Target Selection (pages 41–53): Guo?Jun Zhang and William G. Kaelin
Chapter 4 RNA Interference in Mammals: Journey to the Center of Human Disease (pages 55–72): Patrick J. Paddison and Gregory J. Hannon
Chapter 5 Applications and Issues for Tissue Arrays in Target and Drug Discovery (pages 73–90): Eric Jonasch, Kim?Anh Do, Christopher Logothetis and Timothy J. McDonnell
Chapter 6 Protein Transduction Strategies for Target and Mechanism Validation (pages 91–118): Sergei A. Ezhevsky and Steven F. Dowdy
Chapter 7 Drug Screening: Assay Development Issues (pages 119–140): Steven S. Carroll, James Inglese, Shi?Shan Mao and David B. Olsen
Chapter 8 Gene Microarray Technologies for Cancer Drug Discovery and Development (pages 141–186): Robert H. te Poele, Paul A. Clarke and Paul Workman
Chapter 9 Transgenic Mouse Models of Cancer (pages 187–202): T. J. Bowen and A. Wynshaw?Boris
Chapter 10 Transgenic Versus Xenograft Mouse Models of Cancer: Utility and Issues (pages 203–226): Ming Liu, W. Robert Bishop, Yaolin Wang and Paul Kirschmeier
Chapter 11 Pharmacodynamic Assays in Cancer Drug Discovery: From Preclinical Validation to Clinical Trial Monitoring (pages 227–254): Robert B. Lobell, Nancy E. Kohl and Laura Sepp?Lorenzino
Chapter 12 Pharmacokinetic and Toxicology Issues in Cancer Drug Discovery and Development (pages 255–286): Pamela A. Benfield and Bruce D. Car
Chapter 13 Clinical Development Issues (pages 287–306): Steven D. Averbuch, Michael K. Wolf, Basil F. El?Rayes and Patricia M. LoRusso
Chapter 14 Intellectual Property and Commercialization Issues in Drug Discovery (pages 307–327): Lisa Gail Malseed